Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von SpringheelJack 

Ionis Pharmaceuticals Inc. diskutieren

Ionis Pharmaceuticals Inc.

WKN: A2ACMZ / Symbol: IONS / Name: Ionis Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

46,49 €
6,32 %

Einschätzung Buy
Rendite (%) 10,88 %
Kursziel 68,92
Veränderung
Endet am 09.04.25

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $72.00 to $75.00. They now have an "outperform" rating on the stock.
Ratings data for IONS provided by MarketBeat

Einschätzung Buy
Rendite (%) 10,88 %
Kursziel 55,13
Veränderung
Endet am 09.04.25

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for IONS provided by MarketBeat

Einschätzung Buy
Rendite (%) 16,31 %
Kursziel 53,79
Veränderung
Endet am 10.04.25

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $58.00 price target on the stock.
Ratings data for IONS provided by MarketBeat

Einschätzung Buy
Rendite (%) 22,73 %
Kursziel 55,81
Veränderung
Endet am 08.05.25

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat

Einschätzung Buy
Rendite (%) 24,24 %
Kursziel 76,23
Veränderung
Endet am 08.05.25

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $85.00 to $82.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat

Einschätzung Buy
Rendite (%) 30,74 %
Kursziel 55,31
Veränderung
Endet am 03.06.25

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,49 %
Kursziel 61,44
Veränderung
Endet am 17.07.25

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Bank of America Co. from $64.00 to $67.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 55,09
Veränderung
Endet am 22.07.25

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat